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Available online 14 April 2016Background: In the SURVIVE trial, including 1327 acute heart failure patients, no statistically signiﬁcant difference
between levosimendan and dobutamine in the 180-day all-cause mortality was seen. Country-speciﬁc differ-
ences in outcome were, however, present. In the Finnish sub-population in fact, mortality was signiﬁcantly
lower in levosimendan treated patients. We aim to understand the reasons for this disparity.
Methods: The risk factors for all-causemortality were identiﬁed in thewhole study population usingmultivariate
Cox proportional hazards regression analysis. Those factors were evaluated in the 95 patients of the Finnish sub-
population.
Results: The treatment by country interaction for mortality in Finland vs. other countries was signiﬁcant, p =
0.029. Levosimendan treated patients had a lower 180-day mortality compared to dobutamine treated (17%
vs. 40%, p = 0.023) in the Finnish sub-population. Baseline variables predicting survival in the whole SURVIVE
trial population included age, systolic blood pressure, heart rate, myocardial infarction during admission, levels
of NT-pro-BNP, glucose, creatinine, and alanine transferase, use of ACE inhibitors and β-blockers, oliguria, time
from hospital admission to randomization, history of cardiac arrest, and left ventricular ejection fraction. Finnish
patients were more frequently treated with β-blockers (88% vs. 52%, p b 0.0001), their study treatment was
started earlier (mean ± SD 41 ± 40 h vs. 81 ± 154; p b 0.0001), and they had more often acute myocardial in-
farction at admission (39% vs. 16%, p b 0.0001).
Conclusion: The lower mortality in the Finnish patients treated with levosimendan was associated with higher
use of β-blockers, higher frequency of myocardial infarction at admission, and shorter delay between randomi-
zation and start of treatment.nive
en).
land© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Inotropes1. Introduction
Levosimendan is a calcium sensitizer and ATP-dependent potassium
channel opener [1], developed for the treatment of acute decompensat-
ed heart failure (AHF) [2]. This inodilator has been in clinical use since
year 2000 and is currently available in 60 countries.
The earlier clinical study LIDO (Levosimendan Infusion versus Dobu-
tamine) suggested a mortality beneﬁt with levosimendan in compari-
son with dobutamine in 203 patients with low output heart failure [3].
In the later SURVIVE trial (Levosimendan vs dobutamine for patients
with acute decompensated heart failure) including 1327 patients with
AHF, no statistically signiﬁcant difference in 180-day mortality was
observed between levosimendan and dobutamine [4]. However, inrsity of Helsinki Hospital,
Ltd. This is an open access articlpatients with ongoing beta-blockade, levosimendan outperformed do-
butamine [5].
The SURVIVE trial was conducted at 75 centers in 9 countries (Austria,
Finland, France, Germany, Israel, Latvia, Poland, Russia, and the United
Kingdom). The result as it regards mortality was signiﬁcantly different
among the different participating countries [6,7]. In Finland, mortality
was lower in levosimendan treated patients compared to dobutamine
treated. In this retrospective analysis of the SURVIVE data, we aimed to
ﬁnd explanations for this difference in order to better understand
which kind of patients beneﬁt most of a treatment with levosimendan.
2. Methods
SURVIVEwas a randomized, controlled, parallel-group trial to evalu-
ate the efﬁcacy and safety of dobutamine and levosimendan in 1327
adult patients (aged N18 years) hospitalized due to AHF and meeting
speciﬁed eligibility criteria, including a need for parenteral inotropes.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Kaplan–Meier curves for mortality in Finland and other countries (combined).
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drug. The primary endpoint was all-cause mortality during the 180 days
following randomization. The trial was event rate-driven, requiring 330
deaths. Secondary endpoints included 31-day all-cause mortality and
change in brain natriuretic peptide (BNP) level during the ﬁrst 24 h of
treatment [4].
In this retrospective analysis we identiﬁed the risk factors for worse
outcome in the whole study population by multivariate analysis, and
tested those factors in the two treatment arms of the 95 Finnish
patients.
2.1. Multivariate analysis
All the demographic and baseline variables captured on the case re-
cord form (CRF) of patients in the intent-to-treat (ITT) cohort of
SURVIVE were considered as potential explanatory factors for survival
(Appendix A).
Variables were classiﬁed and evaluated as continuous, categorical
(N2 categories) or binary (two categories) as appropriate.
A Cox proportional hazardsmodelwith forward stepwise addition of
variables was used for multivariate modeling versus all-causemortality
at 180 days. The statistical strength of each variable's contribution to the
prediction of outcomewas expressed as the χ2 statistic with one degree
of freedom. Step forward process had entry criteria of p b 0.10 and var-
iables meeting the criterion of p b 0.05 were retained for further evalu-
ation. Clinical variables identiﬁed in this way provided the elements of
our reference model. The ﬁnal model included categorized/binary vari-
ables for country (Finland vs. other countries), randomized study treat-
ment (levosimendan vs. dobutamine), use of beta-blocking agents, and
previous congestive HF (vs. de novo HF).
All demographic variables and baseline characteristics selected in
the ﬁnal model were compared between Finland and other countries,
using two-group T-test for continuous and Fisher's exact test for cate-
gorical and binary variables. A p value below b0.05 was considered sta-
tistically signiﬁcant.
3. Results
In Finland, levosimendan treated patients had a lower 180-day all-
causemortality: 8/47 (17%) vs. 19/48 (40%), hazard ratio 0.38 [95% con-
ﬁdence interval 0.17, 0.88], p = 0.023, whereas no signiﬁcant differ-
ences between levosimendan and dobutamine in mortality were
observed in the whole study population or in the rest of the study pop-
ulation (Fig. 1). The treatment by country interaction in 180-day mor-
tality for Finland vs. other countries was signiﬁcant (p = 0.029). (See
Fig. 2.)
The baseline characteristics of patients in Finland and in other coun-
tries are presented in Table 1. All the baseline variables collected in the
case report forms (Appendix A) were examined for their inﬂuence onFig. 1. Hazard ratio for 180-day all-cause mortality (levosimendan:dobutamine) in
SURVIVE patients. Treatment by country interaction p = 0.029.survival at 180 days. Factors signiﬁcantly associated with 180-day mor-
tality in the total study population are shown in Table 2. In addition,
beta-blocker use and previous congestive heart failure were included in
the table as earlier analyses suggest that, in those patients, levosimendan
outperforms dobutamine [5], and as the use of beta-blockers has been
consistently shown to improve outcome in heart failure [8].
Of these factors, beta-blocker use (88% vs 52% in Finland and other
countries, respectively), previous congestive heart failure (77% vs
89%), acute myocardial infarction (AMI) during current admission
(39% vs. 16%), time from hospital admission until decision of entry to
the study (41 h vs. 81 h), use of loop diuretics (99% vs. 94%), ascites
(5.3% vs. 20.3%) and peripheral oedema (42% vs. 70%)were signiﬁcantly
different in Finland compared to other countries (Table 2).
There were no statistically signiﬁcant differences in dosing of
levosimendan or dobutamine between Finland and other countries
(Table 3). Also, there were no meaningful differences in adverse events
of special interest (Table 4).
4. Discussion
The SURVIVE study evaluated whether there is a signiﬁcant differ-
ence in 180-day mortality between levosimendan and dobutamine in
patients with AHF and in need of inotropic support. In the whole study
population, there was no signiﬁcant difference in the outcome between
Table 1
Baseline characteristics.
Finland Other countries
Variable Levo
(n = 47)
Dobu
(n = 48)
Total
(n = 95)
Levo
(n = 617)
Dobu
(n = 615)
Total
(n = 1232)
Age; years
mean (SD)
69 (12) 68 (11) 68 (12) 67 (12) 66 (12) 66 (12)
Male gender (%) 19% 25% 22% 26% 31% 28%
BMI; kg/m2
mean (SD)
27 (5) 28 (5) 28 (5) 28 (6) 28 (5) 28 (5)
Systolic BP; mm Hg mean (SD) 113 (15) 113 (19) 113 (17) 116 (18) 116 (19) 116 (19)
Diastolic BP; mm Hg mean (SD) 63 (14) 63 (11) 63 (12) 71 (11) 71 (11) 71 (11)a
Heart rate; bpm mean (SD) 80 (15) 82 (16) 81 (16) 84 (18) 83 (17) 83 (17)
LVEF; %
mean (SD)
23 (4) 23 (5) 23 (5) 24 (5) 24 (5) 24 (5)
Etiology of heart diseasea
Ischemic; % 68% 60% 64% 76% 77% 77%
Hypertension; % 9% 13% 11% 4% 4% 4%
Other; % 23% 27% 25% 19% 19% 19%
Cardiovascular history, %
Pre-existing heart failure 72% 81% 77% 89% 89% 89%a
History of hypertension 47% 56% 52% 62% 65% 64%a
Chronic arrhythmias 60% 69% 64% 57% 54% 56%
Diabetes mellitus 38% 42% 40% 32% 37%b 34%
AMI at index hospitalization 47% 31% 39% 14% 17% 16%a
Selected concomitant medications; %
Beta-blocker 94% 83% 88% 51% 53% 52%a
ACEi/ARB 77% 60% 68% 72% 73% 73%
Aldosterone-antagonist 11% 40%b 25% 55% 58% 56%a
Selected laboratory variables; mean (SD)
B-Hemoglobin; g/dL 12.7 (1.4) 12.5 (1.8) 12.6 (1.6) 13.3 (1.8) 13.4 (1.8) 13.4 (1.8)a
P-Creatinine; μmol/L 110 (41) 125 (47) 118 (44) 125 (56) 124 (62) 125 (59)
P-NT-pro-BNP; ng/L 24,286 (27,764) 28,185 (26,840) 26,256 (27,226) 23,116 (21,049) 24,676 (35,256) 23,895 (31,027)
B-WBC; ×109/L 9.27 (2.79) 9.30 (3.27) 9.28 (3.02) 8.85 (4.17) 8.52 (3.14) 8.69 (3.69)
P-Glucose; mmol/L 7.6 (2.3) 8.3 (3.9) 7.9 (3.2) 7.7 (3.2) 7.9 (3.4) 7.8 (3.3)
Signs and symptoms of heart failure; %
Shortness of breath at rest 100% 100% 100% 95% 95% 95%a
Oliguria 2% 10% 6% 8% 8% 8%
Time to study drug administration; hours mean (SD) 36 (30) 45 (48) 41 (40) 77 (68) 84 (70) 81 (154)a
a p b 0.05 between Finland and other countries, using T-test for continuous variables and χ2 test for categorical and binary variables.
b p b 0.05 between levosimendan and dobutamine within country stratum, using T-test for continuous variables and χ2 test for categorical and binary variables.
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signiﬁcant country-speciﬁc differences inmortality. In Finland alone, the
survival signiﬁcantly favored levosimendan.
We identiﬁed predictors of worse outcome in the whole study pop-
ulation. These are in linewith earlier ﬁndings in other publications. Age,
higher baseline heart rate, lower systolic blood pressure and left ven-
tricular ejection fraction and renal impairment are well known predic-
tors of worse outcome in acute heart failure [9–11]. Higher NT-pro-
BNP, white blood cell, glucose and alanineaminotransferase levels
have also been related to increased mortality [10,12,13]. The use of
ACE inhibitors/angiotensin receptor blockers and beta-blockers has
shown to improve outcome in these patients [14,15].
Most of the predictors of poor outcome showed similar frequency
patients in Finland and other countries. However, beta-blocker use,
prevalence of AMI during current admission, ascites and peripheral oe-
dema, time from hospital admission to study drug treatment, and left
ventricular ejection fraction were signiﬁcantly different.
Ascites and peripheral oedema were less prevalent in the Finnish
population. However, therewere noprespeciﬁed criteria for the diagno-
sis of ascites in the studyprotocol (e.g. ultrasonography) and itmaywell
be that the differences are not exactly representing real differences be-
tween the populations. Therefore, it is difﬁcult to draw conclusions on
the effect, if any, of these baseline variations. The difference in left ven-
tricular ejection fraction values between Finland and other countries at
baseline should also be interpreted with caution.Although mean ejection fraction was statistically lower in Finnish
patients, the numerical difference was very small and probably had no
clinical signiﬁcance.
Remarkably, themean time to studydrug administrationwas almost
twice as long in other countries compared to Finland. As amatter of fact,
by analyzing the data-set of the SURVIVE trial, we found some outlier
data collected for patients who received the treatment (either
levosimendan or placebo) only 25 days after randomization. In this re-
gard, it has been shown that a shorter delay between the hospitalization
and the start of an effective treatment has signiﬁcantly improved out-
come [16]. The importance of early randomization in acute heart failure
trials was recently highlighted [17,18].
In the SURVIVE trial, Finnish patients also had signiﬁcantly more
often AMI infarction during the current admission. Levosimendan has
been shown to exert beneﬁcial effects in this subgroup in earlier studies.
In the RUSSLAN study, levosimendan showed signiﬁcantly lower mor-
tality compared to placebo in 504 patients with AMI and signs of left
ventricular dysfunction [19]. In addition, in several smaller-scale
placebo-controlled studies in PCI-treated patients with acute coronary
syndrome levosimendan improved myocardial stunning [20], coronary
ﬂow and hemodynamics [21], and left ventricular wall motion [22]. In-
deed several meta-analyses, now based on a population of over 6000
patients in randomized clinical trials, provide the general understand-
ing of signiﬁcant beneﬁts for levosimendan in terms of patientmortality
[23]. On the contrary, an overall worse prognosis in the mid-term to
Table 2
Baseline factors associated with increased mortality in the SURVIVE study, and difference in them between Finland and other countries.
Explanatory variable Factors associated with increased
mortality in the SURVIVE study
Difference between Finland and other countries; mean (SD)
where applicable
χ2 score p-Value Hazard ratio Finland (n = 95) Other countries (n = 1232) p-Value
Systolic blood pressure; mm Hg 55.3 b0.0001 0.97 113 (17) 116 (19) 0.1234b
NT-pro-BNP; ng/L 39.2 b0.0001 1.00 26,256 (27,226) 23,895 (31,027) 0.4713b
White blood cell count; ×109/L 32.6 b0.0001 1.05 9.3 (3.0) 8.7 (3.7) 0.0712b
Myocardial infarction during current admission; no vs. yes 24.4 b0.0001 0.49 39% 16% b0.0001c
Creatinine; μmol/L 24.3 b0.0001 1.00 118 (44) 125 (59) 0.1531b
Use of ACE inhibitors or ARBs; yes vs. no 17.5 b0.0001 0.61 68% 73% 0.3419c
Heart rate; bpm 12.2 0.0005 1.01 81 (16) 83 (17) 0.1985b
Oliguria;
no vs. yes
12.1 0.0005 0.57 6% 8% 0.8402c
Age; years 9.8 0.0017 1.02 68 (12) 66 (12) 0.1489b
Time from hospital admission to randomization; hours 8.4 0.0038 1.00 41 (40) 81 (154) b0.0001b
Ascites;
no vs. yes
8.1 0.0044 0.67 5% 20% 0.0001c
Glucose; mmol/L 7.1 0.0079 1.04 7.9 (3.2) 7.8 (3.3) 0.7230b
Alanine transaminase; IU/L 6.9 0.0084 1.00 92 (260) 66 (243) 0.3060b
Cardiopulmonary arrest;
no vs. yes
5.2 0.0221 0.51 1% 2% N0.999c
Peripheral oedema;
no vs. yes
5.1 0.0234 0.75 42% 70% b0.0001c
Use of loop diuretics; yes vs. no 4.6 0.0319 1.74 99% 94% 0.0382c
Coronary artery disease; no vs. yes 4.4 0.0355 0.72 72% 77% 0.2056c
Use of beta blockersa;
yes vs. no
2.4 0.1241 0.83 88% 52% b0.0001c
Previous congestive heart failurea; yes vs. no 0.0 0.9659 1.01 77% 89% 0.0014c
The bold emphasis is for the signiﬁcant values (p b 0.05). and appears self evident
a Fixed terms in Cox proportional hazards stepwise selection model.
b T-test.
c Fisher's.
29M. Kivikko et al. / International Journal of Cardiology 215 (2016) 26–31long-term has indeed been associated with the use of dobutamine in a
meta-analyses by Tacon et al. [24].
In the SURVIVE trial, almost 90% of the Finnish patients were
treated with beta-blockers at baseline, whereas only about half of
the patients in other countries were receiving beta-blockade. In the
LIDO study, the hemodynamic effect of levosimendan on cardiac out-
put and pulmonary capillary wedge pressure was more pronounced
in beta-blocked patients, whereas the opposite was seen with dobu-
tamine [3], which is expected as it is a beta-agonist. In the whole
SURVIVE study population, levosimendan showed superior survival
effect over dobutamine in beta-blocked patients within ﬁve days
after randomization [5].
The study drugs were dosed similarly, with no difference in total
dose or infusion duration, in Finland and other countries. The adverse
event proﬁle showed no difference either.
A play of chance for the different outcome in Finland cannot be ruled
out since the number of patients in the Finnish cohortswas rather small.
However, the most striking differences in baseline characteristics were
the frequencies of beta-blocker users and patients with AMI, and
levosimendan has been earlier shown to beneﬁt these particular patient
populations. The limitations of our study are the relatively small sample
size in each participating country, and the retrospective nature of the
analyses.Table 3
Dosing of levosimendan and dobutamine in Finland and other countries.a
Finland
Levosimendan
(n = 46)
Do
(n
Duration; hours mean (SD) 23.1 (3.6)
Cumulative dose; mg mean (SD) 22.1 (6.3) 14
a No statistically signiﬁcant differences.5. Conclusions
There were country-speciﬁc differences in the outcome in the
SURVIVE trial. In Finland alone, levosimendan showed signiﬁcantly
lower mortality when compared to dobutamine. This may be related
to different baseline characteristics. Beta-blocker usage and AMI at ad-
mission were more frequent and the time to study drug treatment
shorter in Finland; levosimendan may be superior to dobutamine in
these patients and conditions.
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butamine
= 48)
Levosimendan
(n = 614)
Dobutamine
(n = 612)
35.0 (23.6) 23.5 (2.8) 39.7 (45.6)
40.4 (1193.9) 22.6 (5.9) 1128.4 (1879.7)
Table 4
Adverse events of special interest in Finland and other countries.
Adverse events of special interest; n (%) Finland Other countries
Levosimendan
(n = 46)
Dobutamine
(n = 48)
Total
(n = 94)
Levosimendan
(n = 614)
Dobutamine
(n = 612)
Total
(n = 1226)
Atrial arrhythmias 9 (20%) 5 (10%) 14 (15%) 66 (11%) 52 (8%) 118 (10%)
Ventricular arrhythmias 8 (17%) 6 (13%) 14 (15%) 95 (15%) 82 (13%) 177 (14%)
Myocardial ischemia 3 (7%) 5 (10%) 8 (9%) 54 (9%) 66 (11%) 120 (10%)
Hypotension 9 (20%) 9 (19%) 18 (19%) 96 (16%) 84 (14%) 180 (15%)
Renal disorders 3 (7%) 4 (8%) 7 (7%) 40 (7%) 36 (6%) 76 (6%)
Heart failure 9 (20%) 10 (21%) 19 (20%) 119 (19%) 145 (24%) 264 (22%)
Increased blood glucose 3 (7%) 3 (6%) 6 (6%) 26 (4%) 18 (3%) 44 (4%)
Decreased plasma potassium 9 (20%) 6 (13%) 15 (16%) 61 (10%) 36 (6%) 97 (8%)
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forms
A.1. Demographics
• Age
• Sex
• Ethnic origin
• Use of tobacco products
• Current drug abuse
• Country (Finland vs. Others)
• Time from hospital admission to randomization
A.2. Vital signs
• Weight
• Height
• Body mass index
• Heart rate
• Systolic blood pressure
• Diastolic blood pressure
A.3. Baseline central laboratory variables
• Hematocrit
• Hemoglobin
• Platelets
• Red blood cell count
• White blood cell count
• ALT Alanine aminotransferase
• AST Aspartate aminotransferase
• Alkaline phosphatase
• Creatinine
• Glucose
• Potassium
• Sodium
• Brain natriuretic peptide (BNP)
• N-terminal pro brain natriuretic peptide (NT-proBNP)
A.4. Data on initial hospitalization
• Locus from where admitted
• Main reason for hospitalization
• Previous congestive heart failure
• Etiology of congestive heart failure
• Ejection fraction
• Myocardial infarction during current admission• Thrombolytics administered
• Angioplasty
• Cardiopulmonary arrest
• Swan–Ganz catheter
• Mechanical ventilation for heart failure
• Oliguria
A.5. Signs and symptoms of heart failure on admission
• Shortness of breath
• Orthopnea
• Fatigue
• Pulmonary rales
• Radiographic signs of congestion
• Peripheral edema
• Cold extremities
• Peripheral cyanosis
• Diaphoresis
• Ascites
• Mental slowness/confusion
A.6. ECG ﬁndings
• Sinus rhythm, paced rhythm or ECG evidence of atrial ﬁbrillation
• Conduction normal, BBB, AV block or other
• Morphology (abnormal Q waves or T waves, inverted T waves or ST
segment depressed or elevated)
• Baseline PR, QRS, QT, QTcB and QTcF interval
A.7. Cardiovascular history
• Coronary artery disease
• Hypertension
• Diabetes mellitus
• Cerebrovascular symptoms
• Arrhythmias
• Hemodynamically relevant valve disorders
• Other cardiovascular symptoms
A.8. Selected baseline concomitant medications
• ACE inhibitors or ARBs
• β-Blocking agents
• Loop diuretics
• Nitroglycerine
• Aldosterone antagonists
31M. Kivikko et al. / International Journal of Cardiology 215 (2016) 26–31References
[1] Z. Papp, I. Édes, S. Fruhwald, S.G. De Hert, M. Salmenperä, H. Leppikangas, et al.,
Levosimendan: molecular mechanisms and clinical implications: consensus of ex-
perts on the mechanisms of action of levosimendan, Int. J. Cardiol. 159 (2) (2012)
82–87.
[2] M.S. Nieminen, S. Fruhwald, L.M. Heunks, P.K. Suominen, A.C. Gordon, M. Kivikko,
et al., Levosimendan: current data, clinical use and future development, Heart
Lung Vessel. 5 (4) (2013) 227–245.
[3] F. Follath, J.G. Cleland, H. Just, J.G. Papp, H. Scholz, K. Peuhkurinen, et al., Efﬁcacy and
safety of intravenous levosimendan compared with dobutamine in severe low-
output heart failure (the LIDO study): a randomised double-blind trial, Lancet 360
(9328) (2002) 196–202.
[4] A. Mebazaa, M.S. Nieminen, M. Packer, A. Cohen-Solal, F.X. Kleber, S.J. Pocock, et al.,
Levosimendan vs dobutamine for patients with acute decompensated heart failure:
the SURVIVE randomized trial, JAMA 297 (17) (2007) 1883–1891.
[5] A. Mebazaa, M.S. Nieminen, G.S. Filippatos, J.G. Cleland, J.E. Salon, R. Thakkar, et al.,
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-
blockers in SURVIVE, Eur. J. Heart Fail. 11 (3) (2009) 304–311.
[6] A. Mebazaa, The SURVIVE trial: comparison of dobutamine and levosimendan on
survival in acute decompensated heart failure. Program and Abstracts from the
American Heart Association Scientiﬁc Sessions 2005; November 13–16, 2005; Dal-
las, Texas. Late Breaking Clinical Trials IV. (http://www.medscape.org/viewarticle/
523043 [Latest access Feb 21, 2016]).
[7] J.G. Cleland, N. Freemantle, A.P. Coletta, A.L. Clark, Clinical trials update from the
American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II,
SURVIVE, and PROACTIVE, Eur. J. Heart Fail. 8 (1) (2006) 105–110.
[8] R. Bølling, N.M. Scheller, L. Køber, H.E. Poulsen, G.H. Gislason, C. Torp-Pedersen,
Comparison of the clinical outcome of different beta-blockers in heart failure pa-
tients: a retrospective nationwide cohort study, Eur. J. Heart Fail. 16 (6) (2014)
678–684.
[9] J.T. Parissis, M. Nikolaou, A. Mebazaa, I. Ikonomidis, J. Delgado, F. Vilas-Boas, et al.,
Acute pulmonary oedema: clinical characteristics, prognostic factors, and in-
hospital management, Eur. J. Heart Fail. 12 (11) (2010) 1193–1202.
[10] A. Teixeira, J. Parenica, J.J. Park, S. Ishihara, K.F. AlHabib, S. Laribi, et al., Clinical pre-
sentation and outcome by age categories in acute heart failure: results from an in-
ternational observational cohort, Eur. J. Heart Fail. 17 (11) (2015) 1114–1123.
[11] K. Kajimoto, N. Sato, T. Takano, Investigators of the Acute Decompensated Heart
Failure Syndromes (ATTEND) registry, Association of age and baseline systolic
blood pressure with outcomes in patients hospitalized for acute heart failure syn-
dromes, Int. J. Cardiol. 191 (2015) 100–106.
[12] N. Polat, A. Yıldız, M.Z. Bilik, M. Aydın, H. Acet, H. Kaya, et al., The importance of he-
matologic indices in the risk stratiﬁcation of patients with acute decompensated
systolic heart failure, Turk. Kardiyol. Dern. Ars. 43 (2) (2015) 157–165.
[13] V.M. van Deursen, C. Edwards, G. Cotter, B.A. Davison, K. Damman, J.R. Teerlink,
et al., Liver function, in-hospital, and post-discharge clinical outcome in patients
with acute heart failure-results from the relaxin for the treatment of patients with
acute heart failure study, J. Card. Fail. 20 (6) (2014) 407–413.[14] M. Böhm, A. Link, D. Cai, M.S. Nieminen, G.S. Filippatos, R. Salem, et al., Beneﬁcial as-
sociation of β-blocker therapy on recovery from severe acute heart failure treat-
ment: data from the survival of patients with acute heart failure in need of
intravenous inotropic support trial, Crit. Care Med. 39 (5) (2011) 940–944.
[15] J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Böhm, K. Dickstein, et al.,
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart
Failure 2012 of the European Society of Cardiology. Developed in collaboration
with the Heart Failure Association (HFA) of the ESC, Eur. Heart J. 33 (14) (2012)
1787–1784.
[16] A.Mebazaa, M.B. Yilmaz, P. Levy, P. Ponikowski,W.F. Peacock, S. Laribi, et al., Recom-
mendations on pre-hospital & early hospital management of acute heart failure: a
consensus paper from the Heart Failure Association of the European Society of Car-
diology, the European Society of Emergency Medicine and the Society of Academic
Emergency Medicine, Eur. J. Heart Fail. 17 (6) (2015) 544–558.
[17] A. Mebazaa, D. Longrois, M. Metra, C. Mueller, A.M. Richards, L. L. Roessig, et al.,
Agents with vasodilator properties in acute heart failure: how to design successful
trials, Eur. J. Heart Fail. 17 (7) (2015) 652–664.
[18] Y.W.Wong, R.J. Mentz, G.M. Felker, J. Ezekowitz, K. Pieper, G. Heizer, et al., Nesiritide
in patients hospitalized for acute heart failure: does timing matter? Implication for
future acute heart failure trials, Eur. J. Heart Fail. (2016), http://dx.doi.org/10.1002/
ejhf.487.
[19] V.S. Moiseyev, P. Põder, N. Andrejevs, M.Y. Ruda, A.P. Golikov, L.B. Lazebnik, et al.,
Safety and efﬁcacy of a novel calcium sensitizer, levosimendan, in patients with
left ventricular failure due to an acute myocardial infarction. A randomized,
placebo-controlled, double-blind study (RUSSLAN), Eur. Heart. J. 23 (18) (2002)
1422–1432.
[20] S. Sonntag, S. Sundberg, L.A. Lehtonen, F.X. Kleber, The calcium sensitizer
levosimendan improves the function of stunned myocardium after percutaneous
transluminal coronary angioplasty in acute myocardial ischemia, J. Am. Coll. Cardiol.
43 (12) (2004) 2177–2182.
[21] L. De Luca, P. Proietti, A. Celotto, C. Bucciarelli-Ducci, G. Benedetti, A. Di Roma, et al.,
Levosimendan improves hemodynamics and coronary ﬂow reserve after percutane-
ous coronary intervention in patients with acute myocardial infarction and left
ventricular dysfunction, Am. Heart J. 150 (3) (2005) 563–568.
[22] T. Husebye, J. Eritsland, C. Müller, L. Sandvik, H, H. Arnesen, I. Seljeﬂot, et al.,
Levosimendan in acute heart failure following primary percutaneous coronary
intervention-treated acute ST-elevation myocardial infarction. Results from the
LEAF trial: a randomized, placebo-controlled study, Eur. J. Heart Fail. 15 (5)
(2013) 565–572.
[23] P. Pollesello, J. Parissis, M. Kivikko, V.-P. Harjola, Levosimendan meta-analyses: is
there a pattern in the effect on mortality? Int. J. Cardiol. 209 (2016) 77–83.
[24] C.L. Tacon, J. McCaffrey, A. Delaney, Dobutamine for patients with severe heart
failure: a systematic review and meta-analysis of randomised controlled trials,
Intens Care Med 38 (2012) 359–367.
